Double-Punch immunotherapy trial aims to boost survival in tough head and neck cancers
NCT ID NCT07447570
Summary
This study is testing whether adding a new two-drug immunotherapy (iparomlimab and tuvonralimab) to standard radiation and chemotherapy can better control advanced head and neck cancer. It will involve 27 adults with newly diagnosed, locally advanced cancer who haven't had prior treatment. The main goal is to see if more patients are alive and without their cancer getting worse one year after starting this combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital Of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.